Novel biomarkers in glomerular disease.
Novel biomarkers in glomerular disease.
复制标题
肾小球疾病的新型生物标志物。
DOI：
10.1053/j.ackd.2013.12.002
复制
发表时间：
2014-03
影响因子：
2.9
通讯作者：
Kiryluk K
中科院分区：
文献类型：
--
作者：
Caliskan Y;Kiryluk K
肾小球疾病是终末期肾病全球负担的主要贡献者。这些疾病的临床过程和结果是非常可变的，难以预测。临床轨迹范围从良性和自发缓解的状况到有症状和快速进展的疾病。诊断完全基于肾活检的评估，但这种侵入性操作具有多种风险，并且通常无法预测临床过程或对治疗的反应性。然而，遗传学和分子生物学的最新进展促进了这些疾病的新致病机制的阐明。这些发现推动了新型生物标志物的发展，并提供了非侵入性诊断和改进诊断的前景。我们的审查集中在最近出现的主要类型的肾小球疾病，包括伊加肾病，膜性肾病，局灶节段性肾小球硬化症，膜增生性肾小球肾炎的最有前途的新的生物标志物。
Glomerular diseases are major contributors to the global burden of end stage kidney disease. The clinical course and outcome of these disorders are extremely variable and difficult to predict. The clinical trajectories range from a benign and spontaneously remitting condition to a symptomatic and rapidly progressive disease. The diagnosis is based entirely on the evaluation of kidney biopsy, but this invasive procedure carries multiple risks and often fails to predict the clinical course or responsiveness to treatment. However, more recent advances in genetics and molecular biology facilitated elucidation of novel pathogenic mechanisms of these disorders. These discoveries fuel the development of novel biomarkers and offer prospects of non-invasive diagnosis and improved prognostication. Our review focuses on the most promising novel biomarkers that have recently emerged for the major types of glomerular diseases, including IgA nephropathy, membranous nephropathy, focal segmental glomerulosclerosis, and membranoproliferative glomerulonephritis.
登录
查看更多内容
影响因子：
13.2
作者：
Cattran, DC;Rao, P
通讯作者：
Rao, P
影响因子：
6.1
作者：
Espinosa, Mario;Ortega, Rosa;Aljama, Pedro
通讯作者：
Aljama, Pedro
影响因子：
13.6
作者：
Branten, AJW;du Buf-Vereijken, PW;Wetzels, JF
通讯作者：
Wetzels, JF
影响因子：
13.6
作者：
Berthoux, Francois;Suzuki, Hitoshi;Novak, Jan
通讯作者：
Novak, Jan
影响因子：
13.2
作者：
ALAMARTINE, E;SABATIER, JC;BERTHOUX, F
通讯作者：
BERTHOUX, F